Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Neal Swerdlow

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0804
    CA La Jolla 92093
    Phone619-543-6270
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview

      Biography

      Neal Swerdlow, M.D., Ph.D. is Professor of Psychiatry, Director of the Research Residency Track and Vice Chair of Education and Training in the Department of Psychiatry at the University of California, San Diego, School of Medicine. Dr. Swerdlow graduated Summa Cum Laude, Phi Beta Kappa, from Amherst College (Neuroscience) in 1981, received his M.D. and Ph.D. (Neuroscience) from UCSD in 1986, completed the UCSD Psychiatry Residency Program and joined the faculty of the Department of Psychiatry in 1991. Since that time, he has been continuously NIH-funded, was Director of the Psychiatry Core Clerkship for 17 years, and directed separate clinical programs in the treatment of Obsessive Compulsive Disorder (OCD), Tourette Syndrome (TS) and Huntington's Disease (HD).

      Research Interests

      Dr. Swerdlow has published over 250 peer-reviewed research papers, 35 chapters and 1 book. His laboratories study the neural regulation of information processing and its deficiencies in schizophrenia, TS and OCD, and have been home to many dozens of students, from undergraduates to Fellows. Dr. Swerdlow’s career has focused heavily on service to our field and patients. For 10 years, he chaired the Tourette Syndrome Association Scientific Advisory Board, he served the San Diego NAMI for 10 years as a member of their Board of Directors and Chair of their Medical Advisory Board, has been a Program Chair for the American College of Neuropsychopharmacology, chaired and sat on many NIH review committees, was Associate Editor of Behavioral Neuroscience and Editorial Board member of several high-impact journals in our field. Neal is a past recipient of the APA Award for Research in Psychiatry, the ACNP Joel Elkes Award, APA Kempf Award, NAMI Judith Silver Award, TSA Champion of Children's Award, and ACP Laughlin Fellowship, among other awards.


      Collapse Research 
      Collapse Research Activities and Funding
      Psychiatric Research Residency Training Track
      NIH/NIMH R25MH101072Jul 1, 2013 - Jun 30, 2018
      Role: Principal Investigator
      Memantine effects on sensorimotor gating and neurocognition in schizophrenia
      NIH/NIMH R01MH094320Jun 8, 2012 - May 31, 2016
      Role: Principal Investigator
      Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
      NIH/NIMH R34MH093453Jul 1, 2011 - Mar 31, 2014
      Role: Principal Investigator
      Genetics of individual differences in amphetamine effects on startle gating
      NIH/NIDA R03DA027483Sep 1, 2009 - Aug 30, 2011
      Role: Principal Investigator
      Neuroscience at the Boundaries of Neurology and Psychiatry
      NIH/NIMH R25MH076768Sep 30, 2005 - Aug 31, 2008
      Role: Principal Investigator
      Psychiatric Research Residency Training Track
      NIH/NIMH R25MH074508Jul 27, 2005 - Jun 30, 2010
      Role: Principal Investigator
      A Simple Measure for Studying Sensory Gating Deficits
      NIH/NIMH R01MH069589Jul 1, 2004 - Jun 30, 2009
      Role: Principal Investigator
      Neural Basis of Heritable DA-Mediated Gating Deficits
      NIH/NIMH R01MH068366Jul 15, 2003 - Jun 30, 2011
      Role: Principal Investigator
      Pharmacologic augmentation of neurocognition and cognitive training in psychosis
      NIH/NIMH R01MH059803May 1, 1999 - May 31, 2019
      Role: Principal Investigator
      III INTERNATIONAL SYMPOSIUM ON TOURETTE SYNDROME
      NIH/NINDS R13NS038340Sep 25, 1998 - Aug 31, 1999
      Role: Principal Investigator
      Neural Circuitry of Sensorimotor Gating Across Species
      NIH/NIMH K02MH001436Feb 1, 1997 - Jan 31, 2007
      Role: Principal Investigator
      Cortico-Striatal Substrates of Deficient Startle Gating
      NIH/NIMH R01MH053484Jan 15, 1997 - Dec 31, 2010
      Role: Principal Investigator
      SEX DIFFERENCES IN SENSORIMOTOR MODULATION
      NIH/NIMH R03MH054621Aug 1, 1996 - Jul 31, 1998
      Role: Principal Investigator
      STRIATO-PALLIDAL SUBSTRATES OF DEFICIENT STARTLE GATING
      NIH/NIMH R29MH048381Sep 30, 1992 - Aug 31, 1997
      Role: Principal Investigator
      General Clinical Research Center
      NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
      Role: Co-Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Swerdlow N, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2017 May 23. PMID: 28549722.
        View in: PubMed
      2. Light GA, Zhang W, Joshi YB, Bhakta S, Talledo JA, Swerdlow N. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia. Neuropsychopharmacology. 2017 Apr 20. PMID: 28425497.
        View in: PubMed
      3. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlow N, Light GA. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Jan 31. PMID: 28139679.
        View in: PubMed
      4. Swerdlow N, Bhakta SG, Rana BK, Kei J, Chou HH, Talledo JA. Sensorimotor gating in healthy adults tested over a 15 year period. Biol Psychol. 2016 Dec 24. PMID: 28027936.
        View in: PubMed
      5. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Light GA. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2016 Dec 07. PMID: 27926742.
        View in: PubMed
      6. Swerdlow N, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, Rana B, Vinogradov S, Light GA. Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. Schizophr Bull. 2016 Oct 25. PMID: 27798224.
        View in: PubMed
      7. Swerdlow N, Braff DL, Geyer MA. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016 Nov; 30(11):1072-1081. PMID: 27539931.
        View in: PubMed
      8. Cope ZA, Halberstadt AL, van Enkhuizen J, Flynn AD, Breier M, Swerdlow N, Geyer MA, Young JW. Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology (Berl). 2016 Oct; 233(19-20):3513-25. PMID: 27534540; NIHMSID: NIHMS811389 [Available on 10/01/17].
        View in: PubMed
      9. Downs NS, Alderman T, Schneiber K, Swerdlow N. Treat and Teach Our Students Well: College Mental Health and Collaborative Campus Communities. Psychiatr Serv. 2016 May 16; appips201500465. PMID: 27181737.
        View in: PubMed
      10. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow N, Tsuang M, Turetsky B, Radant A, Tsuang DW. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 Jul; 174(1-3):1-9. PMID: 27132484.
        View in: PubMed
      11. Bhakta SG, Chou HH, Rana B, Talledo JA, Balvaneda B, Gaddis L, Light GA, Swerdlow N. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 2016 Jun; 233(12):2399-410. PMID: 27076209.
        View in: PubMed
      12. Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff DL, Swerdlow N, Light GA. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. PMID: 26851143.
        View in: PubMed
      13. Swerdlow CD, Blumenthal T, Swerdlow N. Reawakening research on reducing shock pain. Heart Rhythm. 2016 May; 13(5):1149-50. PMID: 26795457.
        View in: PubMed
      14. Swerdlow N, Light GA. Animal Models of Deficient Sensorimotor Gating in Schizophrenia: Are They Still Relevant? Curr Top Behav Neurosci. 2016; 28:305-25. PMID: 27311762.
        View in: PubMed
      15. Amitai N, Powell S, Weber M, Swerdlow N, Young JW. Negative visuospatial priming in isolation-reared rats: Evidence of resistance to the disruptive effects of amphetamine. Cogn Affect Behav Neurosci. 2015 Dec; 15(4):901-14. PMID: 26220402.
        View in: PubMed
      16. Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. PMID: 26597662.
        View in: PubMed
      17. Greenwood TA, Light GA, Swerdlow N, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 1; 173(4):385-91. PMID: 26441157.
        View in: PubMed
      18. Swerdlow N, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine Effects on Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis. Neuropsychopharmacology. 2015 Jun 11. PMID: 26062785.
        View in: PubMed
      19. Light GA, Swerdlow N. Bending the curve on psychosis outcomes. Lancet Psychiatry. 2015 May; 2(5):365-7. PMID: 26360262.
        View in: PubMed
      20. Gur RC, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. PMID: 25432636.
        View in: PubMed
      21. Light GA, Swerdlow N. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2015 May; 1344(1):105-19. PMID: 25752648.
        View in: PubMed
      22. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. PMID: 25749017.
        View in: PubMed
      23. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff DL, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
        View in: PubMed
      24. Radant AD, Millard SP, Braff DL, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. PMID: 25553977.
        View in: PubMed
      25. Stone WS, Mesholam-Gately RI, Braff DL, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: Comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. PMID: 25497440.
        View in: PubMed
      26. Swerdlow N, Gur RE, Braff DL. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research. Schizophr Res. 2015 Apr; 163(1-3):9-16. PMID: 25454799.
        View in: PubMed
      27. Light GA, Swerdlow N, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff DL, Turetsky BI. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. PMID: 25449710.
        View in: PubMed
      28. Tarasenko MA, Swerdlow N, Makeig S, Braff DL, Light GA. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. PMID: 25352811.
        View in: PubMed
      29. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow N, Tsuang DW, Tsuang MT, Light G. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: Clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. PMID: 25306203.
        View in: PubMed
      30. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) Study: The moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. PMID: 25248939.
        View in: PubMed
      31. Light G, Greenwood TA, Swerdlow N, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Comparison of the Heritability of Schizophrenia and Endophenotypes in the COGS-1 Family Study. Schizophr Bull. 2014 Nov; 40(6):1404-11. PMID: 24903414.
        View in: PubMed
      32. Schmeidler J, Lazzeroni LC, Swerdlow N, Ferreira RP, Braff DL, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833.
        View in: PubMed
      33. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. Is There an Association between Advanced Paternal Age and Endophenotype Deficit Levels in Schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888.
        View in: PubMed
      34. Swerdlow N, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. PMID: 24405980.
        View in: PubMed
      35. Perez VB, Swerdlow N, Braff DL, Näätänen R, Light GA. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014 Jan; 8(1):9-14. PMID: 24325220.
        View in: PubMed
      36. Light GA, Swerdlow N. Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle. Curr Top Behav Neurosci. 2014; 21:293-314. PMID: 24850080.
        View in: PubMed
      37. Swerdlow N, Light GA, Trim RS, Breier MR, Hines SR, Powell SB. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behav Brain Res. 2013 Nov 15; 257:118-28. PMID: 24076151.
        View in: PubMed
      38. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013 Aug 1; 154(3):518-29. PMID: 23911319.
        View in: PubMed
      39. Swerdlow N, Powell SB, Breier MR, Hines SR, Light GA. Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. Neuropharmacology. 2013 Dec; 75:38-46. PMID: 23810830.
        View in: PubMed
      40. Greenwood TA, Swerdlow N, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff DL. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May 1; 170(5):521-32. PMID: 23511790.
        View in: PubMed
      41. Swerdlow N, Hines SR, Herrera SD, Weber M, Breier MR. Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains. Pharmacol Biochem Behav. 2013 May; 106:128-31. PMID: 23567203.
        View in: PubMed
      42. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL, Lazzeroni LC, Gur RE. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. PMID: 23395246.
        View in: PubMed
      43. Chou HH, Talledo JA, Lamb SN, Thompson WK, Swerdlow N. Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults. Psychopharmacology (Berl). 2013 May; 227(1):165-76. PMID: 23314393.
        View in: PubMed
      44. Swerdlow N. Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome. Neurosci Biobehav Rev. 2013 Jul; 37(6):1150-6. PMID: 23017868.
        View in: PubMed
      45. Amitai N, Weber M, Swerdlow N, Sharp RF, Breier MR, Halberstadt AL, Young JW. A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. Neurosci Biobehav Rev. 2013 Jul; 37(6):1139-49. PMID: 23010529.
        View in: PubMed
      46. Light GA, Swerdlow N, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff DL. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
        View in: PubMed
      47. Swerdlow N, Shilling PD, Breier M, Trim RS, Light GA, Marie RS. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology (Berl). 2012 Dec; 224(3):349-62. PMID: 22700037.
        View in: PubMed
      48. Rissling AJ, Braff DL, Swerdlow N, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. PMID: 22608970.
        View in: PubMed
      49. Swerdlow N, Light GA, Breier MR, Shoemaker JM, Saint Marie RL, Neary AC, Geyer MA, Stevens KE, Powell SB. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev Neurosci. 2012; 34(2-3):240-9. PMID: 22572564.
        View in: PubMed
      50. Kirihara K, Rissling AJ, Swerdlow N, Braff DL, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. PMID: 22361076.
        View in: PubMed
      51. Greenwood TA, Light GA, Swerdlow N, Radant AD, Braff DL. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. PMID: 22253750.
        View in: PubMed
      52. Chou HH, Twamley E, Swerdlow N. Towards medication-enhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol. 2012; (213):81-111. PMID: 23027413.
        View in: PubMed
      53. Swerdlow N. Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia. Neuropsychopharmacology. 2012 Jan; 37(1):310-1. PMID: 22157876.
        View in: PubMed
      54. Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow N. Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Res. 2012 Feb 9; 1437:69-76. PMID: 22227455.
        View in: PubMed
      55. Chang WL, Breier MR, Yang A, Swerdlow N. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats. Pharmacol Biochem Behav. 2011 Oct; 99(4):634-8. PMID: 21683731.
        View in: PubMed
      56. Swerdlow N. Are we studying and treating schizophrenia correctly? Schizophr Res. 2011 Aug; 130(1-3):1-10. PMID: 21645998.
        View in: PubMed
      57. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. PMID: 21498463.
        View in: PubMed
      58. Sutherland Owens AN, Miguel EC, Swerdlow N. Sensory gating scales and premonitory urges in Tourette syndrome. ScientificWorldJournal. 2011; 11:736-41. PMID: 21442151.
        View in: PubMed
      59. Swerdlow N, Breier MR, Saint Marie RL. Probing the molecular basis for an inherited sensitivity to the startle-gating disruptive effects of apomorphine in rats. Psychopharmacology (Berl). 2011 Aug; 216(3):401-10. PMID: 21365203.
        View in: PubMed
      60. Stone WS, Giuliano AJ, Tsuang MT, Braff DL, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow N, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. PMID: 21288694.
        View in: PubMed
      61. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow N, Braff DL. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. PMID: 20578033.
        View in: PubMed
      62. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. PMID: 20382002.
        View in: PubMed
      63. Chang WL, Swerdlow N, Breier MR, Thangaraj N, Weber M. Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats. Pharmacol Biochem Behav. 2010 Jun; 95(4):473-8. PMID: 20385162.
        View in: PubMed
      64. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang MT, Turetsky BI, Tsuang DW. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. PMID: 20374545.
        View in: PubMed
      65. Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow N. The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats. Eur Neuropsychopharmacol. 2010 Jun; 20(6):421-5. PMID: 20346635.
        View in: PubMed
      66. Saint Marie RL, Miller EJ, Breier MR, Weber M, Swerdlow N. Projections from ventral hippocampus to medial prefrontal cortex but not nucleus accumbens remain functional after fornix lesions in rats. Neuroscience. 2010 Jun 30; 168(2):498-504. PMID: 20338222.
        View in: PubMed
      67. Chang WL, Geyer MA, Buell MR, Weber M, Swerdlow N. The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behav Pharmacol. 2010 Mar; 21(2):135-43. PMID: 20215963.
        View in: PubMed
      68. Miller EJ, Saint Marie LR, Breier MR, Swerdlow N. Pathways from the ventral hippocampus and caudal amygdala to forebrain regions that regulate sensorimotor gating in the rat. Neuroscience. 2010 Jan 20; 165(2):601-11. PMID: 19854244.
        View in: PubMed
      69. Breier MR, Lewis B, Shoemaker JM, Light GA, Swerdlow N. Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats. Behav Brain Res. 2010 Apr 2; 208(2):560-5. PMID: 20080128.
        View in: PubMed
      70. Swerdlow N. Behavioral neurobiology of schizophrenia and its treatment. Preface. Curr Top Behav Neurosci. 2010; 4:v-vii. PMID: 21312394.
        View in: PubMed
      71. Swerdlow N. Integrative circuit models and their implications for the pathophysiologies and treatments of the schizophrenias. Curr Top Behav Neurosci. 2010; 4:555-83. PMID: 21312413.
        View in: PubMed
      72. Swerdlow N . Behavioral Neurobiology of Schizophrenia and Its Treatment. 2010; 1-657.
      73. Qu Y, Saint Marie RL, Breier MR, Ko D, Stouffer D, Parsons LH, Swerdlow N. Neural basis for a heritable phenotype: differences in the effects of apomorphine on startle gating and ventral pallidal GABA efflux in male Sprague-Dawley and Long-Evans rats. Psychopharmacology (Berl). 2009 Dec; 207(2):271-80. PMID: 19756524.
        View in: PubMed
      74. Swerdlow N, Lelham SA, Sutherland Owens AN, Chang WL, Sassen SD, Talledo JA. Pramipexole effects on startle gating in rats and normal men. Psychopharmacology (Berl). 2009 Sep; 205(4):689-98. PMID: 19506839.
        View in: PubMed
      75. Swerdlow N, Talledo JA. Effects of the first prepulse on the blink response to a startling noise. Behav Neurosci. 2009 Jun; 123(3):607-13. PMID: 19485567.
        View in: PubMed
      76. Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow N. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav. 2009 Aug; 93(2):141-7. PMID: 19426754.
        View in: PubMed
      77. Swerdlow N, van Bergeijk DP, Bergsma F, Weber E, Talledo J. The effects of memantine on prepulse inhibition. Neuropsychopharmacology. 2009 Jun; 34(7):1854-64. PMID: 19242406.
        View in: PubMed
      78. Talledo JA, Sutherland Owens AN, Schortinghuis T, Swerdlow N. Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology (Berl). 2009 May; 204(1):165-75. PMID: 19148623.
        View in: PubMed
      79. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow N. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl). 2009 May; 203(4):723-35. PMID: 19066855.
        View in: PubMed
      80. Weber M, Chang WL, Breier M, Ko D, Swerdlow N. Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol. 2008 Dec; 19(8):786-95. PMID: 19020413.
        View in: PubMed
      81. Qu Y, Swerdlow N, Weber M, Stouffer D, Parsons LH. Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies. Pharmacol Biochem Behav. 2008 Oct; 90(4):686-90. PMID: 18579193.
        View in: PubMed
      82. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. PMID: 18701089.
        View in: PubMed
      83. Swerdlow N, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. PMID: 18568339.
        View in: PubMed
      84. Horan WP, Braff DL, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. PMID: 18406578.
        View in: PubMed
      85. Shilling PD, Saint Marie RL, Shoemaker JM, Swerdlow N. Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathways. Biol Psychiatry. 2008 Apr 15; 63(8):748-58. PMID: 18083141.
        View in: PubMed
      86. Braff DL, Greenwood TA, Swerdlow N, Light GA, Schork NJ. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. PMID: 18458787.
        View in: PubMed
      87. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. PMID: 17984393.
        View in: PubMed
      88. Light GA, Swerdlow N, Braff DL. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. PMID: 18271737.
        View in: PubMed
      89. Weber M, Swerdlow N. Rat strain differences in startle gating-disruptive effects of apomorphine occur with both acoustic and visual prepulses. Pharmacol Biochem Behav. 2008 Jan; 88(3):306-11. PMID: 17900675.
        View in: PubMed
      90. Swerdlow N, Breier M, Mora AB, Ko D, Shoemaker JM. A novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating. Pharmacol Biochem Behav. 2008 Jan; 88(3):280-90. PMID: 17936348.
        View in: PubMed
      91. Swerdlow N, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav. 2007 May; 87(1):1-10. PMID: 17475315.
        View in: PubMed
      92. Swerdlow N, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. PMID: 17346930.
        View in: PubMed
      93. Harte MK, Powell SB, Swerdlow N, Geyer MA, Reynolds GP. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J Neural Transm. 2007 Jul; 114(7):893-8. PMID: 17594127.
        View in: PubMed
      94. Braff DL, Light GA, Swerdlow N. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. PMID: 17161386.
        View in: PubMed
      95. Swerdlow N, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. PMID: 17146007.
        View in: PubMed
      96. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow N. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007 Jan; 33(1):69-94. PMID: 17135482.
        View in: PubMed
      97. Swerdlow N, Blumenthal TD, Sutherland AN, Weber E, Talledo JA. Effects of prepulse intensity, duration, and bandwidth on perceived intensity of startling acoustic stimuli. Biol Psychol. 2007 Mar; 74(3):389-95. PMID: 17118517.
        View in: PubMed
      98. Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J, Kanes SJ, Hans M, Lowman AM, Dan N, Winey KI, Swerdlow N, Siegel SJ. Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology (Berl). 2007 Feb; 190(2):201-11. PMID: 17119931.
        View in: PubMed
      99. Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, Erenberg G, Jankovic J, Juncos J, Leckman JF, Swerdlow N, Visser-Vandewalle V, Vitek JL. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006 Nov; 21(11):1831-8. PMID: 16991144.
        View in: PubMed
      100. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. PMID: 17035358.
        View in: PubMed
      101. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff DL, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow N, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. PMID: 17023145.
        View in: PubMed
      102. Saint Marie RL, Neary AC, Shoemaker JM, Swerdlow N. The effects of apomorphine and D-amphetamine on striatal c-Fos expression in Sprague-Dawley and Long Evans rats and their F1 progeny. Brain Res. 2006 Nov 13; 1119(1):203-14. PMID: 16979142.
        View in: PubMed
      103. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow N, Braff DL. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 1; 60(11):1231-40. PMID: 16893524.
        View in: PubMed
      104. Swerdlow N, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett. 2006 Jul 10; 402(1-2):40-5. PMID: 16644125.
        View in: PubMed
      105. Swerdlow N, Krupin AS, Bongiovanni MJ, Shoemaker JM, Goins JC, Hammer RP. Heritable differences in the dopaminergic regulation of behavior in rats: relationship to D2-like receptor G-protein function. Neuropsychopharmacology. 2006 Apr; 31(4):721-9. PMID: 16123742.
        View in: PubMed
      106. Swerdlow N, Bongiovanni MJ, Tochen L, Shoemaker JM. Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome. Psychopharmacology (Berl). 2006 Jun; 186(2):246-54. PMID: 16583235.
        View in: PubMed
      107. Swerdlow N, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. PMID: 16123772.
        View in: PubMed
      108. Swerdlow N, Talledo J, Sutherland AN, Nagy D, Shoemaker JM. Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology. 2006 Sep; 31(9):2011-21. PMID: 16482083.
        View in: PubMed
      109. Swerdlow N, Sprock J, Braff DL. Prepulse-elicited motor reactions do not differ between schizophrenia patients and control subjects. Behav Neurosci. 2006 Feb; 120(1):224-7. PMID: 16492135.
        View in: PubMed
      110. Swerdlow N, Sutherland AN. Preclinical models relevant to Tourette syndrome. Adv Neurol. 2006; 99:69-88. PMID: 16536353.
        View in: PubMed
      111. Swerdlow N, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL. Reduced startle gating after D1 blockade: effects of concurrent D2 blockade. Pharmacol Biochem Behav. 2005 Oct; 82(2):293-9. PMID: 16188305.
        View in: PubMed
      112. Hsieh MH, Swerdlow N, Braff DL. Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol Psychiatry. 2006 Mar 15; 59(6):555-9. PMID: 16169529.
        View in: PubMed
      113. Swerdlow N. Tourette syndrome: current controversies and the battlefield landscape. Curr Neurol Neurosci Rep. 2005 Sep; 5(5):329-31. PMID: 16131414.
        View in: PubMed
      114. Swerdlow N, Sutherland AN. Using animal models to develop therapeutics for Tourette Syndrome. Pharmacol Ther. 2005 Dec; 108(3):281-93. PMID: 15970330.
        View in: PubMed
      115. Swerdlow N, Stephany NL, Talledo J, Light G, Braff DL, Baeyens D, Auerbach PP. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. PMID: 15804542.
        View in: PubMed
      116. Braff DL, Light GA, Ellwanger J, Sprock J, Swerdlow N. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 1; 57(7):817-20. PMID: 15820241.
        View in: PubMed
      117. Swerdlow N, Talledo JA, Braff DL. Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the 'Pacific Rim'. Psychiatr Genet. 2005 Mar; 15(1):61-5. PMID: 15722959.
        View in: PubMed
      118. Swerdlow N. Much ado about (almost) nothing: response to 'prepulse lost and regained'. Psychopharmacology (Berl). 2005 Jun; 179(4):893-4. PMID: 15645219.
        View in: PubMed
      119. Swerdlow N, Stephany N, Wasserman LC, Talledo J, Sharp R, Minassian A, Auerbach PP. Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophr Res. 2005 Jan 1; 72(2-3):169-83. PMID: 15560962.
        View in: PubMed
      120. Shoemaker JM, Saint Marie RL, Bongiovanni MJ, Neary AC, Tochen LS, Swerdlow N. Prefrontal D1 and ventral hippocampal N-methyl-D-aspartate regulation of startle gating in rats. Neuroscience. 2005; 135(2):385-94. PMID: 16125865.
        View in: PubMed
      121. Swerdlow N, Kuczenski R, Goins JC, Crain SK, Ma LT, Bongiovanni MJ, Shoemaker JM. Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists. Pharmacol Biochem Behav. 2005 Feb; 80(2):203-11. PMID: 15680173.
        View in: PubMed
      122. Harte MK, Powell SB, Reynolds LM, Swerdlow N, Geyer MA, Reynolds GP. Reduced N-acetylaspartate in the temporal cortex of rats reared in isolation. Biol Psychiatry. 2004 Aug 15; 56(4):296-9. PMID: 15312819.
        View in: PubMed
      123. Swerdlow N, Talledo J, Shoemaker JM, Codon K, Goins J, Auerbach PP. Weak prepulses inhibit but do not elicit startle in rats and humans. Biol Psychiatry. 2004 Jun 15; 55(12):1195-8. PMID: 15184039.
        View in: PubMed
      124. Swerdlow N, Shoemaker JM, Crain S, Goins J, Onozuka K, Auerbach PP. Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. Pharmacol Biochem Behav. 2004 Feb; 77(2):291-302. PMID: 14751457.
        View in: PubMed
      125. Swerdlow N, Shoemaker JM, Noh HR, Ma L, Gaudet I, Munson M, Crain S, Auerbach PP. The ventral hippocampal regulation of prepulse inhibition and its disruption by apomorphine in rats are not mediated via the fornix. Neuroscience. 2004; 123(3):675-85. PMID: 14706779.
        View in: PubMed
      126. Swerdlow N, Shoemaker JM, Platten A, Pitcher L, Goins J, Auerbach PP. Heritable differences in the dopaminergic regulation of sensorimotor gating. I. Apomorphine effects on startle gating in albino and hooded outbred rat strains and their F1 and N2 progeny. Psychopharmacology (Berl). 2004 Aug; 174(4):441-51. PMID: 15300358.
        View in: PubMed
      127. Swerdlow N, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A. Heritable differences in the dopaminergic regulation of sensorimotor gating. II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology (Berl). 2004 Aug; 174(4):452-62. PMID: 15300359.
        View in: PubMed
      128. Swerdlow N, Shoemaker JM, Platten A, Pitcher L, Goins J, Crain S. Heritable differences in the effects of amphetamine but not DOI on startle gating in albino and hooded outbred rat strains. Pharmacol Biochem Behav. 2003 Apr; 75(1):191-7. PMID: 12759127.
        View in: PubMed
      129. Swerdlow N, Stephany N, Wasserman LC, Talledo J, Sharp R, Auerbach PP. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology (Berl). 2003 Sep; 169(3-4):314-20. PMID: 12610717.
        View in: PubMed
      130. Shoemaker JM, Pitcher L, Noh HR, Swerdlow N. Quetiapine produces a prolonged reversal of the sensorimotor gating-disruptive effects of basolateral amygdala lesions in rats. Behav Neurosci. 2003 Feb; 117(1):136-43. PMID: 12619916.
        View in: PubMed
      131. Swerdlow N, Platten A, Hanlon FM, Martinez ZA, Printz MP, Auerbach P. Sensitivity to sensorimotor gating-disruptive effects of apomorphine in two outbred parental rat strains and their F1 and N2 progeny. Neuropsychopharmacology. 2003 Feb; 28(2):226-34. PMID: 12589375.
        View in: PubMed
      132. Powell SB, Geyer MA, Preece MA, Pitcher LK, Reynolds GP, Swerdlow N. Dopamine depletion of the nucleus accumbens reverses isolation-induced deficits in prepulse inhibition in rats. Neuroscience. 2003; 119(1):233-40. PMID: 12763084.
        View in: PubMed
      133. Swerdlow N, Wasserman LC, Talledo JA, Casas R, Bruins P, Stephany NL. Prestimulus modification of the startle reflex: relationship to personality and physiological markers of dopamine function. Biol Psychol. 2003 Jan; 62(1):17-26. PMID: 12505765.
        View in: PubMed
      134. Swerdlow N, Pitcher L, Noh HR, Shoemaker JM. Startle gating in rats is disrupted by chemical inactivation but not D2 stimulation of the dorsomedial thalamus. Brain Res. 2002 Oct 25; 953(1-2):246-54. PMID: 12384258.
        View in: PubMed
      135. Swerdlow N, Stephany N, Wasserman LC, Talledo J, Shoemaker J, Auerbach PP. Amphetamine effects on prepulse inhibition across-species: replication and parametric extension. Neuropsychopharmacology. 2003 Apr; 28(4):640-50. PMID: 12655308.
        View in: PubMed
      136. Powell SB, Swerdlow N, Pitcher LK, Geyer MA. Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiol Behav. 2002 Sep; 77(1):55-64. PMID: 12213502.
        View in: PubMed
      137. Swerdlow N, Stephany N, Shoemaker JM, Ross L, Wasserman LC, Talledo J, Auerbach PP. Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons. Psychopharmacology (Berl). 2002 Oct; 164(1):82-92. PMID: 12373422.
        View in: PubMed
      138. Swerdlow N, Shoemaker JM, Stephany N, Wasserman L, Ro HJ, Geyer MA. Prestimulus effects on startle magnitude: sensory or motor? Behav Neurosci. 2002 Aug; 116(4):672-81. PMID: 12148934.
        View in: PubMed
      139. Swerdlow N, Shoemaker JM, Pitcher L, Platten A, Kuczenski R, Eleey CC, Auerbach P. Genetic differences in startle gating-disruptive effects of apomorphine: evidence for central mediation. Behav Neurosci. 2002 Aug; 116(4):682-90. PMID: 12148935.
        View in: PubMed
      140. Swerdlow N, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, Cadenhead K, Auerbach PP. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl). 2002 May; 161(2):189-201. PMID: 11981599.
        View in: PubMed
      141. Martinez ZA, Platten A, Pollack E, Shoemaker J, Ro H, Pitcher L, Geyer MA, Swerdlow N. "Typical" but not "atypical" antipsychotic effects on startle gating deficits in prepubertal rats. Psychopharmacology (Berl). 2002 Apr; 161(1):38-46. PMID: 11967629.
        View in: PubMed
      142. Swerdlow N, Platten A, Shoemaker J, Pitcher L, Auerbach P. Effects of pergolide on sensorimotor gating of the startle reflex in rats. Psychopharmacology (Berl). 2001 Nov; 158(3):230-40. PMID: 11713612.
        View in: PubMed
      143. Swerdlow N, Karban B, Ploum Y, Sharp R, Geyer MA, Eastvold A. Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an "fMRI-friendly" startle paradigm. Biol Psychiatry. 2001 Oct 15; 50(8):578-85. PMID: 11690592.
        View in: PubMed
      144. Swerdlow N, Platten A, Kim YK, Gaudet I, Shoemaker J, Pitcher L, Auerbach P. Sensitivity to the dopaminergic regulation of prepulse inhibition in rats: evidence for genetic, but not environmental determinants. Pharmacol Biochem Behav. 2001 Oct-Nov; 70(2-3):219-26. PMID: 11701191.
        View in: PubMed
      145. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow N. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl). 2001 Jul; 156(2-3):117-54. PMID: 11549216.
        View in: PubMed
      146. Swerdlow N, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl). 2001 Jul; 156(2-3):194-215. PMID: 11549223.
        View in: PubMed
      147. Braff DL, Geyer MA, Swerdlow N. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001 Jul; 156(2-3):234-58. PMID: 11549226.
        View in: PubMed
      148. Swerdlow N. Obsessive-compulsive disorder and tic syndromes. Med Clin North Am. 2001 May; 85(3):735-55. PMID: 11349482.
        View in: PubMed
      149. Swerdlow N, Halim N, Hanlon FM, Platten A, Auerbach PP. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res Bull. 2001 May 1; 55(1):71-7. PMID: 11427340.
        View in: PubMed
      150. Geyer MA, Swerdlow N. Measurement of startle response, prepulse inhibition, and habituation. Curr Protoc Neurosci. 2001 May; Chapter 8:Unit 8.7. PMID: 18428548.
        View in: PubMed
      151. Swerdlow N, Hanlon FM, Henning L, Kim YK, Gaudet I, Halim ND. Regulation of sensorimotor gating in rats by hippocampal NMDA: anatomical localization. Brain Res. 2001 Apr 20; 898(2):195-203. PMID: 11306005.
        View in: PubMed
      152. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow N. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001 Apr 15; 49(1-2):171-8. PMID: 11343875.
        View in: PubMed
      153. Swerdlow N, Eastvold A, Uyan KM, Ploum Y, Cadenhead K. Matching strategies for drug studies of prepulse inhibition in humans. Behav Pharmacol. 2001 Feb; 12(1):45-52. PMID: 11270511.
        View in: PubMed
      154. Swerdlow N, Young AB. Neuropathology in Tourette syndrome: an update. Adv Neurol. 2001; 85:151-61. PMID: 11530425.
        View in: PubMed
      155. Farid M, Martinez ZA, Geyer MA, Swerdlow N. Regulation of sensorimotor gating of the startle reflex by serotonin 2A receptors. Ontogeny and strain differences. Neuropsychopharmacology. 2000 Dec; 23(6):623-32. PMID: 11063918.
        View in: PubMed
      156. Martinez ZA, Oostwegel J, Geyer MA, Ellison GD, Swerdlow N. "Early" and "late" effects of sustained haloperidol on apomorphine- and phencyclidine-induced sensorimotor gating deficits. Neuropsychopharmacology. 2000 Nov; 23(5):517-27. PMID: 11027917.
        View in: PubMed
      157. Cadenhead KS, Swerdlow N, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry. 2000 Oct; 157(10):1660-8. PMID: 11007721.
        View in: PubMed
      158. Swerdlow N, Eastvold A, Gerbranda T, Uyan KM, Hartman P, Doan Q, Auerbach P. Effects of caffeine on sensorimotor gating of the startle reflex in normal control subjects: impact of caffeine intake and withdrawal. Psychopharmacology (Berl). 2000 Sep; 151(4):368-78. PMID: 11026744.
        View in: PubMed
      159. Halim ND, Swerdlow N. Distributed neurodegenerative changes 2-28 days after ventral hippocampal excitotoxic lesions in rats. Brain Res. 2000 Aug 4; 873(1):60-74. PMID: 10915811.
        View in: PubMed
      160. Swerdlow N, Martinez ZA, Hanlon FM, Platten A, Farid M, Auerbach P, Braff DL, Geyer MA. Toward understanding the biology of a complex phenotype: rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci. 2000 Jun 1; 20(11):4325-36. PMID: 10818168.
        View in: PubMed
      161. Swerdlow N, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol. 2000 Jun; 11(3-4):185-204. PMID: 11103873.
        View in: PubMed
      162. Martinez ZA, Halim ND, Oostwegel JL, Geyer MA, Swerdlow N. Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats. Pharmacol Biochem Behav. 2000 Mar; 65(3):449-57. PMID: 10683485.
        View in: PubMed
      163. Swerdlow N, Taaid N, Halim N, Randolph E, Kim YK, Auerbach P. Hippocampal lesions enhance startle gating-disruptive effects of apomorphine in rats: a parametric assessment. Neuroscience. 2000; 96(3):523-36. PMID: 10717433.
        View in: PubMed
      164. Feifel D, Moutier CY, Swerdlow N. Attitudes toward psychiatry as a prospective career among students entering medical school. Am J Psychiatry. 1999 Sep; 156(9):1397-402. PMID: 10484951.
        View in: PubMed
      165. Swerdlow N, Geyer MA, Hartman PL, Sprock J, Auerbach PP, Cadenhead K, Perry W, Braff DL. Sex differences in sensorimotor gating of the human startle reflex: all smoke? Psychopharmacology (Berl). 1999 Sep; 146(2):228-32. PMID: 10525760.
        View in: PubMed
      166. Doan QT, Swerdlow N. Preliminary findings with a new Vietnamese Stroop test. Percept Mot Skills. 1999 Aug; 89(1):173-82. PMID: 10544412.
        View in: PubMed
      167. Geyer MA, Swerdlow N, Lehmann-Masten V, Teschendorf HJ, Traut M, Gross G. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats. J Pharmacol Exp Ther. 1999 Aug; 290(2):716-24. PMID: 10411583.
        View in: PubMed
      168. Martinez ZA, Ellison GD, Geyer MA, Swerdlow N. Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Neuropsychopharmacology. 1999 Jul; 21(1):28-39. PMID: 10379517.
        View in: PubMed
      169. Hartston HJ, Swerdlow N. Visuospatial priming and stroop performance in patients with obsessive compulsive disorder. Neuropsychology. 1999 Jul; 13(3):447-57. PMID: 10447305.
        View in: PubMed
      170. Swerdlow N, Braff DL, Geyer MA. Cross-species studies of sensorimotor gating of the startle reflex. Ann N Y Acad Sci. 1999 Jun 29; 877:202-16. PMID: 10415651.
        View in: PubMed
      171. Braff DL, Swerdlow N, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999 Apr; 156(4):596-602. PMID: 10200740.
        View in: PubMed
      172. Farber RH, Swerdlow N, Clementz BA. Saccadic performance characteristics and the behavioural neurology of Tourette's syndrome. J Neurol Neurosurg Psychiatry. 1999 Mar; 66(3):305-12. PMID: 10084528.
        View in: PubMed
      173. Martinez ZA, Ellison GD, Geyer MA, Swerdlow N. Effects of sustained cocaine exposure on sensorimotor gating of startle in rats. Psychopharmacology (Berl). 1999 Mar; 142(3):253-60. PMID: 10208317.
        View in: PubMed
      174. Swerdlow N, Hartston HJ, Hartman PL. Enhanced visual latent inhibition in obsessive-compulsive disorder. Biol Psychiatry. 1999 Feb 15; 45(4):482-8. PMID: 10071722.
        View in: PubMed
      175. Cadenhead KS, Carasso BS, Swerdlow N, Geyer MA, Braff DL. Prepulse inhibition and habituation of the startle response are stable neurobiological measures in a normal male population. Biol Psychiatry. 1999 Feb 1; 45(3):360-4. PMID: 10023514.
        View in: PubMed
      176. Roman MJ, Delis DC, Filoteo JV, Demadura TL, Paulsen J, Swerdlow N, Swenson MR, Salmon D, Butters N, Shults C. Is there a "subcortical" profile of attentional dysfunction? A comparison of patients with Huntington's and Parkinson's diseases on a global-local focused attention task. J Clin Exp Neuropsychol. 1998 Dec; 20(6):873-84. PMID: 10484698.
        View in: PubMed
      177. Swerdlow N. Startle in Tourette's syndrome. Biol Psychiatry. 1998 Nov 1; 44(9):935-6. PMID: 9807655.
        View in: PubMed
      178. Swerdlow N. What role models? Commentary on Robbins' homology in behavioural pharmacology: an approach to animal models of human cognition. Behav Pharmacol. 1998 Nov; 9(7):529-31. PMID: 9862078.
        View in: PubMed
      179. Swerdlow N, Bakshi V, Waikar M, Taaid N, Geyer MA. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl). 1998 Nov; 140(1):75-80. PMID: 9862405.
        View in: PubMed
      180. Swerdlow N, Taaid N, Oostwegel JL, Randolph E, Geyer MA. Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav Pharmacol. 1998 Sep; 9(5-6):389-96. PMID: 9832924.
        View in: PubMed
      181. Hart S, Zreik M, Carper R, Swerdlow N. Localizing haloperidol effects on sensorimotor gating in a predictive model of antipsychotic potency. Pharmacol Biochem Behav. 1998 Sep; 61(1):113-9. PMID: 9715813.
        View in: PubMed
      182. Bakshi VP, Swerdlow N, Braff DL, Geyer MA. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine. Biol Psychiatry. 1998 Mar 15; 43(6):436-45. PMID: 9532349.
        View in: PubMed
      183. Swerdlow N, Varty GB, Geyer MA. Discrepant findings of clozapine effects on prepulse inhibition of startle: is it the route or the rat? Neuropsychopharmacology. 1998 Jan; 18(1):50-6. PMID: 9408918.
        View in: PubMed
      184. Swerdlow N, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull. 1998; 24(2):285-301. PMID: 9613626.
        View in: PubMed
      185. Kodsi MH, Swerdlow N. Reduced prepulse inhibition after electrolytic lesions of nucleus accumbens subregions in the rat. Brain Res. 1997 Oct 31; 773(1-2):45-52. PMID: 9409703.
        View in: PubMed
      186. Kodsi MH, Swerdlow N. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Neurosci Lett. 1997 Aug 8; 231(2):103-7. PMID: 9291151.
        View in: PubMed
      187. Feifel D, Swerdlow N. The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin. Neurosci Lett. 1997 Jun 20; 229(1):5-8. PMID: 9224788.
        View in: PubMed
      188. Feifel D, Minor KL, Dulawa S, Swerdlow N. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 1997 Jun 20; 760(1-2):80-4. PMID: 9237521.
        View in: PubMed
      189. Farber RH, Clementz BA, Swerdlow N. Characteristics of open- and closed-loop smooth pursuit responses among obsessive-compulsive disorder, schizophrenia, and nonpsychiatric individuals. Psychophysiology. 1997 Mar; 34(2):157-62. PMID: 9090264.
        View in: PubMed
      190. Swerdlow N, Hartman PL, Auerbach PP. Changes in sensorimotor inhibition across the menstrual cycle: implications for neuropsychiatric disorders. Biol Psychiatry. 1997 Feb 15; 41(4):452-60. PMID: 9034539.
        View in: PubMed
      191. Wan FJ, Swerdlow N. The basolateral amygdala regulates sensorimotor gating of acoustic startle in the rat. Neuroscience. 1997 Feb; 76(3):715-24. PMID: 9135045.
        View in: PubMed
      192. Kodsi MH, Swerdlow N. Regulation of prepulse inhibition by ventral pallidal projections. Brain Res Bull. 1997; 43(2):219-28. PMID: 9222535.
        View in: PubMed
      193. Braff DL, Swerdlow N. Neuroanatomy of schizophrenia. Schizophr Bull. 1997; 23(3):509-12. PMID: 9327513.
        View in: PubMed
      194. Swerdlow N, Bakshi V, Geyer MA. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther. 1996 Dec; 279(3):1290-9. PMID: 8968353.
        View in: PubMed
      195. Wan FJ, Caine SB, Swerdlow N. The ventral subiculum modulation of prepulse inhibition is not mediated via dopamine D2 or nucleus accumbens non-NMDA glutamate receptor activity. Eur J Pharmacol. 1996 Oct 24; 314(1-2):9-18. PMID: 8957213.
        View in: PubMed
      196. Wan FJ, Swerdlow N. Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res. 1996 May 25; 722(1-2):168-76. PMID: 8813362.
        View in: PubMed
      197. Swerdlow N, Braff DL, Hartston H, Perry W, Geyer MA. Latent inhibition in schizophrenia. Schizophr Res. 1996 May; 20(1-2):91-103. PMID: 8794497.
        View in: PubMed
      198. Wan FJ, Taaid N, Swerdlow N. Do D1/D2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology. 1996 Apr; 14(4):265-74. PMID: 8924194.
        View in: PubMed
      199. Clementz BA, Farber RH, Lam MN, Swerdlow N. Ocular motor responses to unpredictable and predictable smooth pursuit stimuli among patients with obsessive-compulsive disorder. J Psychiatry Neurosci. 1996 Jan; 21(1):21-8. PMID: 8580114.
        View in: PubMed
      200. Bakshi VP, Geyer MA, Taaid N, Swerdlow N. A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol. 1995 Dec; 6(8):801-809. PMID: 11224383.
        View in: PubMed
      201. Swerdlow N, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA. Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology (Berl). 1995 Nov; 122(1):27-34. PMID: 8711061.
        View in: PubMed
      202. Lipska BK, Swerdlow N, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl). 1995 Nov; 122(1):35-43. PMID: 8711062.
        View in: PubMed
      203. Kodsi MH, Swerdlow N. Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato-pallidal circuitry. Behav Neurosci. 1995 Oct; 109(5):912-28. PMID: 8554715.
        View in: PubMed
      204. Wan FJ, Geyer MA, Swerdlow N. Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology (Berl). 1995 Aug; 120(4):433-41. PMID: 8539324.
        View in: PubMed
      205. Swerdlow N, Geyer MA, Perry W, Cadenhead K, Braff DL. Drug screening in "normal" controls. Biol Psychiatry. 1995 Jul 15; 38(2):123-4. PMID: 7578645.
        View in: PubMed
      206. Kodsi MH, Swerdlow N. Ventral pallidal GABA-A receptors regulate prepulse inhibition of acoustic startle. Brain Res. 1995 Jun 26; 684(1):26-35. PMID: 7583201.
        View in: PubMed
      207. Paulsen JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow N, Swenson MR. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995 May; 45(5):951-6. PMID: 7746413.
        View in: PubMed
      208. Caine SB, Geyer MA, Swerdlow N. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat. Neuropsychopharmacology. 1995 Apr; 12(2):139-45. PMID: 7779242.
        View in: PubMed
      209. Swerdlow N, Filion D, Geyer MA, Braff DL. "Normal" personality correlates of sensorimotor, cognitive, and visuospatial gating. Biol Psychiatry. 1995 Mar 1; 37(5):286-99. PMID: 7748980.
        View in: PubMed
      210. Swerdlow N, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry. 1995 Feb; 58(2):192-200. PMID: 7876851.
        View in: PubMed
      211. Braff DL, Swerdlow N, Geyer MA. Gating and habituation deficits in the schizophrenia disorders. Clin Neurosci. 1995; 3(2):131-9. PMID: 7583619.
        View in: PubMed
      212. Bakshi VP, Swerdlow N, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 1994 Nov; 271(2):787-94. PMID: 7965797.
        View in: PubMed
      213. Wan FJ, Geyer MA, Swerdlow N. Accumbens D2 modulation of sensorimotor gating in rats: assessing anatomical localization. Pharmacol Biochem Behav. 1994 Sep; 49(1):155-63. PMID: 7816867.
        View in: PubMed
      214. Swerdlow N, Britton KT. Alphaxalone, a steroid anesthetic, inhibits the startle-enhancing effects of corticotropin releasing factor, but not strychnine. Psychopharmacology (Berl). 1994 Jun; 115(1-2):141-6. PMID: 7862886.
        View in: PubMed
      215. Swerdlow N, Zisook D, Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Psychopharmacology (Berl). 1994 May; 114(4):675-8. PMID: 7855231.
        View in: PubMed
      216. Kodsi MH, Swerdlow N. Quinolinic acid lesions of the ventral striatum reduce sensorimotor gating of acoustic startle in rats. Brain Res. 1994 Apr 18; 643(1-2):59-65. PMID: 8032933.
        View in: PubMed
      217. Swerdlow N, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry. 1994 Feb; 51(2):139-54. PMID: 8297213.
        View in: PubMed
      218. Swerdlow N, Auerbach P, Monroe SM, Hartston H, Geyer MA, Braff DL. Men are more inhibited than women by weak prepulses. Biol Psychiatry. 1993 Aug 15; 34(4):253-60. PMID: 8399822.
        View in: PubMed
      219. Swerdlow N, Koob GF, Cador M, Lorang M, Hauger RL. Pituitary-adrenal axis responses to acute amphetamine in the rat. Pharmacol Biochem Behav. 1993 Jul; 45(3):629-37. PMID: 8392732.
        View in: PubMed
      220. Swerdlow N. Dopamine and depression: circuitous logic? Biol Psychiatry. 1993 May 15; 33(10):757-8. PMID: 8353174.
        View in: PubMed
      221. Swerdlow N, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav. 1993 Mar; 44(3):741-4. PMID: 8451276.
        View in: PubMed
      222. Swerdlow N, Benbow CH, Zisook S, Geyer MA, Braff DL. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry. 1993 Feb 15; 33(4):298-301. PMID: 8471686.
        View in: PubMed
      223. Swerdlow N, Geyer MA. Prepulse inhibition of acoustic startle in rats after lesions of the pedunculopontine tegmental nucleus. Behav Neurosci. 1993 Feb; 107(1):104-17. PMID: 8447948.
        View in: PubMed
      224. Wan FJ, Swerdlow N. Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats. Psychopharmacology (Berl). 1993; 113(1):103-9. PMID: 7862814.
        View in: PubMed
      225. Caine SB, Geyer MA, Swerdlow N. Hippocampal modulation of acoustic startle and prepulse inhibition in the rat. Pharmacol Biochem Behav. 1992 Dec; 43(4):1201-8. PMID: 1475305.
        View in: PubMed
      226. Swerdlow N, Caine SB, Geyer MA. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacology (Berl). 1992; 108(1-2):189-95. PMID: 1410139.
        View in: PubMed
      227. Swerdlow N, Caine SB, Braff DL, Geyer MA. The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. J Psychopharmacol. 1992 Jan; 6(2):176-90. PMID: 22291349.
        View in: PubMed
      228. Pulvirenti L, Swerdlow N, Koob GF. Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol Biochem Behav. 1991 Dec; 40(4):841-5. PMID: 1687766.
        View in: PubMed
      229. Swerdlow N, Hauger R, Irwin M, Koob GF, Britton KT, Pulvirenti L. Endocrine, immune, and neurochemical changes in rats during withdrawal from chronic amphetamine intoxication. Neuropsychopharmacology. 1991 Aug; 5(1):23-31. PMID: 1657016.
        View in: PubMed
      230. Swerdlow N, Keith VA, Braff DL, Geyer MA. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther. 1991 Feb; 256(2):530-6. PMID: 1825226.
        View in: PubMed
      231. Koob GF, Swerdlow N, Vaccarino F, Hubner C, Pulvirenti L, Weiss F. Functional output of the basal forebrain. Adv Exp Med Biol. 1991; 295:291-305. PMID: 1776573.
        View in: PubMed
      232. Caine SB, Geyer MA, Swerdlow N. Carbachol infusion into the dentate gyrus disrupts sensorimotor gating of startle in the rat. Psychopharmacology (Berl). 1991; 105(3):347-54. PMID: 1798831.
        View in: PubMed
      233. Swerdlow N, Caine SB, Geyer MA. Opiate-dopamine interactions in the neural substrates of acoustic startle gating in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 1991; 15(3):415-26. PMID: 1862221.
        View in: PubMed
      234. Swerdlow N, Braff DL, Geyer MA. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Res. 1990 Nov 5; 532(1-2):146-50. PMID: 2282510.
        View in: PubMed
      235. Geyer MA, Swerdlow N, Mansbach RS, Braff DL. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull. 1990 Sep; 25(3):485-98. PMID: 2292046.
        View in: PubMed
      236. Swerdlow N, Gierz M, Berkowitz A, Nemiroff R, Lohr J. Electroconvulsive therapy in a patient with severe tic and major depressive episode. J Clin Psychiatry. 1990 Jan; 51(1):34-5. PMID: 2295590.
        View in: PubMed
      237. Davis M, Mansbach RS, Swerdlow N, Campeau S, Braff DL, Geyer MA. Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats. Psychopharmacology (Berl). 1990; 102(1):1-4. PMID: 2392496.
        View in: PubMed
      238. Swerdlow N, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl). 1990; 100(3):413-6. PMID: 2315438.
        View in: PubMed
      239. Swerdlow N, Braff DL, Masten VL, Geyer MA. Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology (Berl). 1990; 101(3):414-20. PMID: 2114026.
        View in: PubMed
      240. Koob GF, Cole BJ, Swerdlow N, Le Moal M, Britton KT. Stress, performance, and arousal: focus on CRF. NIDA Res Monogr. 1990; 97:163-76. PMID: 2174122.
        View in: PubMed
      241. Swerdlow N, Andia AM. Trazodone-fluoxetine combination for treatment of obsessive-compulsive disorder. Am J Psychiatry. 1989 Dec; 146(12):1637. PMID: 2589561.
        View in: PubMed
      242. Swerdlow N, Britton KT, Koob GF. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology. 1989 Dec; 2(4):285-92. PMID: 2610824.
        View in: PubMed
      243. Pulvirenti L, Swerdlow N, Koob GF. Microinjection of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats. Neurosci Lett. 1989 Aug 28; 103(2):213-8. PMID: 2771183.
        View in: PubMed
      244. Swerdlow N, Koob GF. Norepinephrine stimulates behavioral activation in rats following depletion of nucleus accumbens dopamine. Pharmacol Biochem Behav. 1989 Jul; 33(3):595-9. PMID: 2511575.
        View in: PubMed
      245. Gold LH, Swerdlow N, Koob GF. The role of mesolimbic dopamine in conditioned locomotion produced by amphetamine. Behav Neurosci. 1988 Aug; 102(4):544-52. PMID: 3139012.
        View in: PubMed
      246. Ruegg RG, Zisook S, Swerdlow N. Depression in the aged. An overview. Psychiatr Clin North Am. 1988 Mar; 11(1):83-99. PMID: 3288982.
        View in: PubMed
      247. Weinger MB, Swerdlow N, Millar WL. Acute postoperative delirium and extrapyramidal signs in a previously healthy parturient. Anesth Analg. 1988 Mar; 67(3):291-5. PMID: 3344981.
        View in: PubMed
      248. Koob GF, Swerdlow N. The functional output of the mesolimbic dopamine system. Ann N Y Acad Sci. 1988; 537:216-27. PMID: 3059925.
        View in: PubMed
      249. Tazi A, Swerdlow N, LeMoal M, Rivier J, Vale W, Koob GF. Behavioral activation by CRF: evidence for the involvement of the ventral forebrain. Life Sci. 1987 Jul 6; 41(1):41-9. PMID: 3496511.
        View in: PubMed
      250. Swerdlow N, Koob GF. Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry. Brain Res. 1987 Jun 2; 412(2):233-43. PMID: 3607466.
        View in: PubMed
      251. Swerdlow N, Amalric M, Koob GF. Nucleus accumbens opiate-dopamine interactions and locomotor activation in the rat: evidence for a pre-synaptic locus. Pharmacol Biochem Behav. 1987 Apr; 26(4):765-9. PMID: 3110795.
        View in: PubMed
      252. Swerdlow N, Koob GF. Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behavioral and Brain Sciences. 1987; 10:197-245.
      253. Amalric M, Koob GF, Creese I, Swerdlow N. "Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat. Life Sci. 1986 Nov 24; 39(21):1985-93. PMID: 2946915.
        View in: PubMed
      254. Amalric M, Blasco TA, Smith NT, Lee DE, Swerdlow N, Koob GF. 'Catatonia' produced by alfentanil is reversed by methylnaloxonium microinjections into the brain. Brain Res. 1986 Oct 29; 386(1-2):287-95. PMID: 3022882.
        View in: PubMed
      255. Blasco TA, Lee D, Amalric M, Swerdlow N, Smith NT, Koob GF. The role of the nucleus raphe pontis and the caudate nucleus in alfentanil rigidity in the rat. Brain Res. 1986 Oct 29; 386(1-2):280-6. PMID: 3096494.
        View in: PubMed
      256. Downs NS, Britton KT, Gibbs DM, Koob GF, Swerdlow N. Supersensitive endocrine response to physostigmine in dopamine-depleted rats: a model of depression? Biol Psychiatry. 1986 Jul; 21(8-9):775-86. PMID: 3015269.
        View in: PubMed
      257. Swerdlow N, Vaccarino FJ, Amalric M, Koob GF. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol Biochem Behav. 1986 Jul; 25(1):233-48. PMID: 2875470.
        View in: PubMed
      258. Bakhit C, Swerdlow N. Behavioral changes following central injection of cysteamine in rats. Brain Res. 1986 Feb 12; 365(1):159-63. PMID: 2868783.
        View in: PubMed
      259. Swerdlow N, Braff DL, Geyer MA, Koob GF. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry. 1986 Jan; 21(1):23-33. PMID: 3080033.
        View in: PubMed
      260. Vaccarino FJ, Amalric M, Swerdlow N, Koob GF. Blockade of amphetamine but not opiate-induced locomotion following antagonism of dopamine function in the rat. Pharmacol Biochem Behav. 1986 Jan; 24(1):61-5. PMID: 3080760.
        View in: PubMed
      261. Swerdlow N, Geyer MA, Vale WW, Koob GF. Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl). 1986; 88(2):147-52. PMID: 3081925.
        View in: PubMed
      262. Swerdlow N, Koob GF, Aldenhoff JB. The effects of verapamil on the locomotor-activating properties of corticotropin releasing factor (CRF) in the rat. Psychoneuroendocrinology. 1986; 11(2):237-40. PMID: 3489244.
        View in: PubMed
      263. Swerdlow N, Lee D, Koob GF, Vaccarino FJ. Effects of chronic dietary lithium on behavioral indices of dopamine denervation supersensitivity in the rat. J Pharmacol Exp Ther. 1985 Nov; 235(2):324-9. PMID: 3932641.
        View in: PubMed
      264. Swerdlow N, Vaccarino FJ, Koob GF. Effects of naloxone on heroin-, amphetamine- and caffeine-stimulated locomotor activity in the rat. Pharmacol Biochem Behav. 1985 Sep; 23(3):499-501. PMID: 4048244.
        View in: PubMed
      265. Swerdlow N, Koob GF. Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat. Pharmacol Biochem Behav. 1985 Aug; 23(2):303-7. PMID: 3877311.
        View in: PubMed
      266. Swerdlow N, Koob GF. The neural substrates of apomorphine-stimulated locomotor activity following denervation of the nucleus accumbens. Life Sci. 1984 Dec 17; 35(25):2537-44. PMID: 6096659.
        View in: PubMed
      267. Koob GF, Swerdlow N, Seeligson M, Eaves M, Sutton R, Rivier J, Vale W. Effects of alpha-flupenthixol and naloxone on CRF-induced locomotor activation. Neuroendocrinology. 1984 Nov; 39(5):459-64. PMID: 6096752.
        View in: PubMed
      268. Swerdlow N, Swanson LW, Koob GF. Substantia innominata: critical link in the behavioral expression of mesolimbic dopamine stimulation in the rat. Neurosci Lett. 1984 Sep 7; 50(1-3):19-24. PMID: 6493625.
        View in: PubMed
      269. Swerdlow N, Swanson LW, Koob GF. Electrolytic lesions of the substantia innominata and lateral preoptic area attenuate the 'supersensitive' locomotor response to apomorphine resulting from denervation of the nucleus accumbens. Brain Res. 1984 Jul 23; 306(1-2):141-8. PMID: 6087974.
        View in: PubMed
      270. Swerdlow N, Koob GF. Restrained rats learn amphetamine-conditioned locomotion, but not place preference. Psychopharmacology (Berl). 1984; 84(2):163-6. PMID: 6438675.
        View in: PubMed
      271. Swerdlow N, van der Kooy D, Koob GF, Wenger JR. Cholecystokinin produces conditioned place-aversions, not place-preferences, in food-deprived rats: evidence against involvement in satiety. Life Sci. 1983 May 2; 32(18):2087-93. PMID: 6843283.
        View in: PubMed
      272. van der Kooy D, Swerdlow N, Koob GF. Paradoxical reinforcing properties of apomorphine: effects of nucleus accumbens and area postrema lesions. Brain Res. 1983 Jan 17; 259(1):111-8. PMID: 6824923.
        View in: PubMed
      273. Sorenson CA, Swerdlow N. The effect of tail pinch on the acoustic startle response in rats. Brain Res. 1982 Sep 9; 247(1):105-13. PMID: 7127106.
        View in: PubMed
      Neal's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _